Cargando…

Delivery of Intraocular Triamcinolone Acetonide in the Treatment of Macular Edema

Macular edema (ME) is one of the eventual outcomes of various intraocular and systemic pathologies. The pathogenesis for ME is not yet entirely understood; however, some of the common risk factors for its development have been identified. While this investigation will not discuss the numerous etiolo...

Descripción completa

Detalles Bibliográficos
Autores principales: Pickrell, Aaron, Harris, Alon, Ngo, Sandra, Amireskandari, Annahita, Stewart, Erin, Siesky, Brent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3834899/
https://www.ncbi.nlm.nih.gov/pubmed/24300190
http://dx.doi.org/10.3390/pharmaceutics4010230
Descripción
Sumario:Macular edema (ME) is one of the eventual outcomes of various intraocular and systemic pathologies. The pathogenesis for ME is not yet entirely understood; however, some of the common risk factors for its development have been identified. While this investigation will not discuss the numerous etiologies of ME in detail, it appraises the two most widely studied delivery modalities of intraocular corticosteroids in the treatment of ME—intravitreal injection (IVI) and sub-Tenon’s infusion (STI). A thorough review of the medical literature was conducted to identify the efficacy and safety of IVI and STI, specifically for the administration of triamcinolone acetonide (TA), in the setting of ME in an attempt to elucidate a preferred steroid delivery modality for treatment of ME.